(VIANEWS) – SSR Mining (SSRM), Amphastar Pharmaceuticals (AMPH), Greenland Technologies Holding Corporation (GTEC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SSR Mining (SSRM)
45.2% sales growth and 4.99% return on equity
SSR Mining Inc., together with its subsidiaries, engages in the acquisition, exploration, development, and operation of precious metal resource properties in Turkey and the Americas. The company explores for gold, silver, copper, lead, and zinc deposits. Its projects include the Çöpler Gold mine located in Erzincan, Turkey; the Marigold mine located in Humboldt County, Nevada, the United States; the Seabee Gold Operation located in Saskatchewan, Canada; and the Puna Operations in Jujuy, Argentina. The company was formerly known as Silver Standard Resources Inc. and changed its name to SSR Mining Inc. in August 2017. SSR Mining Inc. was incorporated in 1946 and is based in Denver, Colorado.
Earnings Per Share
As for profitability, SSR Mining has a trailing twelve months EPS of $0.8.
PE Ratio
SSR Mining has a trailing twelve months price to earnings ratio of 15.92. Meaning, the purchaser of the share is investing $15.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.99%.
Volume
Today’s last reported volume for SSR Mining is 1232510 which is 27.04% above its average volume of 970135.
Moving Average
SSR Mining’s value is way under its 50-day moving average of $14.32 and way below its 200-day moving average of $14.93.
2. Amphastar Pharmaceuticals (AMPH)
36.7% sales growth and 18.73% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $1.83.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 25.01. Meaning, the purchaser of the share is investing $25.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.73%.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals’s stock is valued at $45.76 at 06:22 EST, way below its 52-week high of $67.66 and way higher than its 52-week low of $26.76.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amphastar Pharmaceuticals’s EBITDA is 73.58.
Volume
Today’s last reported volume for Amphastar Pharmaceuticals is 638319 which is 40.43% above its average volume of 454520.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18%, now sitting on 540.89M for the twelve trailing months.
Previous days news about Amphastar Pharmaceuticals(AMPH)
- Amphastar pharmaceuticals (amph) rises as market takes a dip: key facts. According to Zacks on Monday, 23 October, "Investors will be eagerly watching for the performance of Amphastar Pharmaceuticals in its upcoming earnings disclosure. ", "Valuation is also important, so investors should note that Amphastar Pharmaceuticals has a Forward P/E ratio of 16.34 right now. "
3. Greenland Technologies Holding Corporation (GTEC)
34.2% sales growth and 8.31% return on equity
Greenland Technologies Holding Corporation, through its subsidiaries, develops and manufactures transmission and drivetrain systems for material handling machineries and electric vehicles, and electric industrial vehicles in the People's Republic of China and internationally. The company offers transmission products for forklift trucks that are used in manufacturing and logistic applications, such as factories, workshops, warehouses, fulfillment centers, shipyards, and seaports. It also develops robotic cargo carriers. The company was founded in 2006 and is based in Hangzhou, the People's Republic of China.
Earnings Per Share
As for profitability, Greenland Technologies Holding Corporation has a trailing twelve months EPS of $0.31.
PE Ratio
Greenland Technologies Holding Corporation has a trailing twelve months price to earnings ratio of 8.48. Meaning, the purchaser of the share is investing $8.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.31%.
Yearly Top and Bottom Value
Greenland Technologies Holding Corporation’s stock is valued at $2.63 at 06:22 EST, way below its 52-week high of $5.25 and way above its 52-week low of $1.13.
Volume
Today’s last reported volume for Greenland Technologies Holding Corporation is 13444 which is 94.15% below its average volume of 230004.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 50% and positive 137.5% for the next.
4. Huazhu Group (HTHT)
33.6% sales growth and 10.64% return on equity
H World Group Limited, together with its subsidiaries, develops leased and owned, manachised, and franchised hotels primarily in the People's Republic of China. The company operates hotels under its own brands, such as HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, Ibis Hotel, JI Hotel, Orange Hotel, Starway Hotel, Ibis Styles Hotel, CitiGO Hotel, Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, MAXX by Steigenberger, Jaz in the City, Grand Mercure, Steigenberger Icon, and Song Hotels. The company was formerly known as Huazhu Group Limited and changed its name to H World Group Limited in June 2022. The company was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Huazhu Group has a trailing twelve months EPS of $0.46.
PE Ratio
Huazhu Group has a trailing twelve months price to earnings ratio of 80.54. Meaning, the purchaser of the share is investing $80.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.64%.
Volume
Today’s last reported volume for Huazhu Group is 634408 which is 48.64% below its average volume of 1235230.
5. TriMas Corporation (TRS)
23.2% sales growth and 7.43% return on equity
TriMas Corporation manufactures and provides products for consumer products, aerospace, and industrial end markets worldwide. It operates in three segments: Packaging, Aerospace, and Specialty Products. The Packaging segment offers specialty polymeric and steel closure and dispensing systems, including dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, flexible spouts, and agricultural closures; polymeric jar products; integrated dispensers; bag-in-box products; aseptic closures; industrial closures and flex spouts; and single-bodied and assembled caps and closures under the Rieke, Taplast, Affaba & Ferrari, Stolz, and Rapak brands. The Aerospace segment provides fasteners, collars, blind bolts, rivets, ducting and connectors for air management systems, and machined parts and components to original equipment manufacturers, supply chain distributors, MRO/aftermarket providers, and tier one suppliers for commercial, maintenance, repair, and operations (MRO); and military and defense aerospace applications and platforms under the Monogram Aerospace Fasteners, Allfast Fastening Systems, Mac Fasteners, RSA Engineered Products, and Martinic Engineering brands. The Specialty Products segment offers steel cylinders for use in the transportation, storage, and dispensing of compressed gases under the Norris Cylinder brand; natural gas powered wellhead engines, compressors, and replacement parts for oil and natural gas production, and other industrial and commercial markets under the Arrow brand; and spare parts for various industrial engines. The company sells its products through a direct sales force, third-party agents, and distributors. TriMas Corporation was incorporated in 1986 and is headquartered in Bloomfield Hills, Michigan.
Earnings Per Share
As for profitability, TriMas Corporation has a trailing twelve months EPS of $1.14.
PE Ratio
TriMas Corporation has a trailing twelve months price to earnings ratio of 21.25. Meaning, the purchaser of the share is investing $21.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.43%.
Yearly Top and Bottom Value
TriMas Corporation’s stock is valued at $24.23 at 06:22 EST, way under its 52-week high of $31.89 and way higher than its 52-week low of $21.41.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TriMas Corporation’s EBITDA is 41.87.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 1, 2023, the estimated forward annual dividend rate is 0.16 and the estimated forward annual dividend yield is 0.66%.
6. Intuitive Surgical (ISRG)
20.2% sales growth and 12.76% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Intuitive Surgical has a trailing twelve months EPS of $3.98.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 69.72. Meaning, the purchaser of the share is investing $69.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.76%.
Moving Average
Intuitive Surgical’s worth is below its 50-day moving average of $293.47 and below its 200-day moving average of $287.05.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12%, now sitting on 6.85B for the twelve trailing months.
Volume
Today’s last reported volume for Intuitive Surgical is 1282210 which is 28.13% below its average volume of 1784180.
7. Hexcel Corporation (HXL)
11.7% sales growth and 9.47% return on equity
Hexcel Corporation, together with its subsidiaries, develops, manufactures, and markets structural materials for use in commercial aerospace, space and defense, and industrial markets. It operates through two segments, Composite Materials and Engineered Products. The Composite Materials segment manufactures and markets carbon fibers, fabrics and specialty reinforcements, prepregs and other fiber-reinforced matrix materials, structural adhesives, honeycomb, molding compounds, tooling materials, polyurethane systems, and laminates that are used in military and commercial aircraft, wind turbine blades, recreational products, and other industrial applications, as well as in automotive, marine, and trains. The Engineered Products segment manufactures and markets aircraft structures and finished aircraft components, including wing to body fairings, wing panels, flight deck panels, door liners, rotorcraft blades, spars, and tip caps; and aircraft structural sub-components and semi-finished components used in rotorcraft blades, engine nacelles, and aircraft surfaces, such as flaps, wings, elevators, and fairings. The company sells its products directly through its managers, product managers, and sales personnel, as well as through independent distributors and manufacturer representatives in the Americas, Europe, the Asia Pacific, India, and Africa. Hexcel Corporation was founded in 1946 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Hexcel Corporation has a trailing twelve months EPS of $1.75.
PE Ratio
Hexcel Corporation has a trailing twelve months price to earnings ratio of 39.04. Meaning, the purchaser of the share is investing $39.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.47%.
